Stay updated on ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2. Removed the funding-lapse notice and the older Revision: v3.4.1.SummaryDifference0.5%

- Check21 days agoChange DetectedA government funding lapse notice was added at the top of the page, warning that information may not be up to date and that the NIH Clinical Center is open, and the site revision label was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded Show glossary option and a new 'Last Update Submitted that Met QC Criteria' label. Updated capitalization of 'No FEAR Act Data' and the page revision to v3.4.0 (from v3.3.4).SummaryDifference0.3%

- Check42 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the prior Revision: v3.3.3.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section listing Texas as a study location. Replaced the old standalone 'Texas Locations' item with the consolidated Locations section.SummaryDifference0.2%

- Check91 days agoChange DetectedMinor editorial wording changes were made to the Publications section to describe automatic PubMed content, and a page revision version notice was updated. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.